Clik here to view.
Clik here to view.
Vertex Announces Availability of Cystic Fibrosis Medicine KALYDECO®...
LONDON Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that KALYDECO® (ivacaftor) will be available to eligible patients with cystic fibrosis (CF) in New Zealand from March 1....
View ArticleClik here to view.
Arima GenomicsがシリーズAの資金調達を完了
サンディエゴ （ビジネスワイヤ） — ゲノムのシーケンスと構造がヒトの健康と疾患で果たす役割についての理解を促進するための研究ツールに主眼を置く企業のArima Genomics, Inc.は、シリーズAラウンドの資金調達が完了したことを発表します。アジレント・テクノロジー（NYSE: A）とCowin Venture（凱風創投）が本ラウンドを主導し、Vectr...
View ArticleClik here to view.
Arima Genomics完成A轮融资
圣迭戈 (美国商业资讯)–Arima Genomics, Inc.是一家专注于研究工具的公司，这些工具用于增进对基因组顺序和结构的认识，从而了解其在人类健康和疾病中的作用，该公司宣布已完成A轮融资。Agilent Technologies, Inc. (NYSE: A)和Cowin Venture领投，Vectr Ventures和Berkeley Catalyst Fund跟投。...
View ArticleClik here to view.
武田宣布美国FDA授予ALUNBRIG® (brigatinib)作为ALK+转移性非小细胞肺癌一线治疗的补充新药申请优先审理
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(TSE:4502/NYSE:TAK)今天宣布，美国食品药品管理局(FDA)已授予该公司ALUNBRIG...
View ArticleClik here to view.
武田薬品、ALK陽性転移性非小細胞肺がんに対するファーストライン治療薬としてのALUNBRIG®（ブリガチニブ）の適応追加申請を米国FDAが優先審査に指定と発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
Gemini Therapeutics and Singapore Eye Research Institute Enter Into Research...
CAMBRIDGE, Mass. Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry Age-related Macular Degeneration (AMD) and linked ocular disorders, today...
View ArticleClik here to view.
Arcus Biosciences and Taiho Pharmaceutical Co., Ltd. Jointly Announce Taiho’s...
HAYWARD, Calif. Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, and Taiho Pharmaceutical Co. Ltd., (“Taiho”),...
View ArticleClik here to view.
Bioventus认可EXOGEN长达25年经过验证的骨愈合功效
北卡罗莱纳州达勒姆 (美国商业资讯)–骨科解决方案的全球领导者Bioventus认可其EXOGEN超声骨愈合系统长达25年经过验证的骨愈合功效。EXOGEN使用低强度脉冲超声波(LIPUS)来帮助刺激机体的自然骨愈合机制并促进骨折愈合。对于无法自行愈合的骨折，其愈合率达86% 1，对于有适应证的新发骨折，愈合速度提高38% 2, 3。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
New Cancer Treatment Developed at NTHU
HSINCHU, Taiwan A research team led by Dr. Yunching Chen and Tsai-Te Lu of National Tsing Hua University have recently developed a new treatment for cancer, in which blood vessels within malignant...
View ArticleClik here to view.
Antisense Therapeutics Announces Appointment of US-based Consultant Medical...
MELBOURNE, Australia Antisense Therapeutics Limited (ASX:ANP) is pleased to advise of the appointment of Gil Price M.D. as Consultant Medical Director. Dr. Price is a clinical physician trained in...
View ArticleClik here to view.
Inflazome’s Somalix Demonstrates Positive Safety, Tolerability and...
DUBLIN & CAMBRIDGE, United Kingdom & BRISBANE, Australia Inflazome (inflazome.com), the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation,...
View ArticleClik here to view.
Harbour BioMed Receives U.S. FDA IND Approval for Phase 2 Clinical Trial and...
CAMBRIDGE, Mass. & ROTTERDAM, Netherlands & SUZHOU, China Harbour BioMed (HBM) today announced U.S. Food and Drug Administration (FDA) approval of its Investigational New Drug (IND)...
View ArticleClik here to view.
NuProbe Announces Licensing Deal with Oxford Nanopore
HOUSTON & SHANGHAI NuProbe Global, a global molecular diagnostics company based in Shanghai, China and Houston, TX, has signed an agreement with Oxford Nanopore Technologies, where Oxford...
View ArticleClik here to view.
Harbour BioMed Announces U.S. FDA Approval of IND for Its Next Generation...
CAMBRIDGE, Mass. & ROTTERDAM, Netherlands & SUZHOU, China Harbour BioMed (HBM) today announced U.S. Food and Drug Administration (FDA) approval of its Investigational New Drug (IND)...
View ArticleClik here to view.
TransEnterix Announces St. Marianna University School of Medicine Toyoko...
RESEARCH TRIANGLE PARK, N.C. TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive...
View ArticleClik here to view.
Takeda Receives Positive CHMP Opinion for ALUNBRIG® (brigatinib) as a...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human...
View ArticleClik here to view.
Now, Get A Free Knock-out Mouse: The Improved Sperm-freezing Technology...
SEOUL, South Korea Macrogen (KOSDAQ: 038290), the Korean precision medicine biotech company, is hosting a ‘Now, Get A Free Knock-out Mouse!’ event on a first-come, first-served basis. The ‘Now, Get...
View ArticleClik here to view.
武田薬品が一部の一般用医薬品およびノンコア資産のアシノへの売却を完了
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:4502/NYSE:TAK）（「武田薬品」）は本日、当社グロース＆エマージング マーケッツ ビジネス ユニット（GEM...
View ArticleClik here to view.
武田完成向Acino出售部分非处方药和非核心资产的交易
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)（“武田”）今天宣布已完成其先前宣布的一项交易，即以逾2亿美元的总价值向Acino出售其增长与新兴市场业务部门(GEM...
View Article